varvis® webinar series
We are excited to announce the brand new varvis® webinar series! Together with professionals in medical and clinical genetics and valued partners from industry and academia, we put together a programme that covers latest developments and best practices as well as deep-dive sessions covering many important topics including IVDR, liquid biopsy, whole exome analysis or variant interpretation and our user group meeting.
Upcoming Webinar
Pushing the boundaries –
The limit of detection in NGS liquid biopsy
When? July 8, 2021, 4pm
NGS laboratories must comply with numerous regulations and guidelines, and strive, at the same time, to deliver the best possible analytical procedures. In this webinar our three speakers will showcase the latest advancements in NGS liquid biopsy technologies and demonstrate how these novel assays can be properly validated and tailored to the specific use case. Register now and learn more about what is necessary to find the best toolset for liquid biopsy using NGS and the optimum assay design. We will talk about the different aspects demonstrating how to ensure the highest sensitivity and precision while keeping the assay cost-efficient for routine diagnostics and automating quality control to meet international guidelines.
Speakers
Dr. Andreas Polten,
Agilent Technologies
Dr. Ben Liesfeld, Limbus Medical Technologies GmbH
Dr. Denny Schanze,
Intitute for Human Genetics, University Hospital of Magdeburg
Presented by:
Webinars on-demand
Webinar on-demand:
Pushing the boundaries
The limit of detection in NGS liquid biopsy
July 8, 2021
NGS laboratories must comply with numerous regulations and guidelines, and strive, at the same time, to deliver the best possible analytical procedures. In this webinar our three speakers will showcase the latest advancements in NGS liquid biopsy technologies and demonstrate how these novel assays can be properly validated and tailored to the specific use case.
Presented by:
Webinar on-demand:
The IVDR and its impact on clinical diagnostics
How the IVDR will turn laboratory diagnostics in Europe upside down
May 6, 2021
Genetic diagnostic tests that are compliant with IVDD or IVDR are currently available only for a very small number of indications. Most of the genetic tests performed today are based on so-called Laboratory Developed Tests (LDT). The IVDR significantly increases the regulatory requirements for these LDTs and therefore has a high impact on the business and operation of diagnostic laboratories across Europe. In this webinar we will discuss what this means for your daily routine and how you need to deal with this challenge.
Presented by:
Webinar on-demand (German):
IVDR und genetische Diagnostik
Wie die IVDR die Labordiagnostik in Deutschland auf den Kopf stellen wird
February 24, 2021
Nur für eine geringe Zahl von Indikationen in der genetischen Diagnostik sind heute tatsächlich nach IVDD oder IVDR entwickelte CE-IVD-Tests verfügbar. Die meisten der aktuell durchgeführten genetischen Untersuchungen basieren auf sog. Laboratory Developed Tests (LDT). Die IVDR erhöht die regulatorischen Anforderungen an diese LDT erheblich und hat daher sehr konkrete Auswirkungen auf die tägliche Arbeit von Diagnostik-Labors in Deutschland. Was das für Sie bedeutet und wie Sie mit dieser Herausforderung umgehen müssen, erfahren Sie in diesem Webinar.
Presented by:
Webinar on-demand:
The challenge of variant interpretation
Leveraging genetic and clinical evidence to improve the diagnosis of rare diseases
December 9, 2020
Due to the introduction of improved, more cost efficient target capture technologies, NGS-based applications have become the standard of care in human genetics. Large NGS assays and exome analysis generate huge amounts of data that needs to be processed and interpreted and is often underutilizes in clinical practice. The identification and interpretation of relevant genetic variants to provide accurate clinical recommendations is still considered a major challenge, as various genetics and clinical aspects need to be carefully evaluated.
Presented by:
Webinar on-demand:
One assay to rule them all
Why exome analysis is ready to replace NGS panels and conventional CNV detection
September 22, 2020
Supreme target enrichment and validated NGS analysis software enable us to perform exome sequencing as a standard first step diagnostic. In this webinar, our speakers will tell you from their own perspective why exome analysis is ready to replace targeted NGS panels and conventional CNV detection as a single assay approach in clinical routine. Exome analysis is not only efficient and adequate for clinical diagnostics, it is in fact the new standard of care.
Presented by:
Webinar on-demand:
Liquid biopsy in breast cancer using NGS
September 10, 2020
NGS-based liquid biopsy assays combine an ultralow detection limit with broad genomic coverage and therefore offer a much more comprehensive testing strategy. However, the complexity of the wetlab process and the data processing have previously been challenging obstacles. In our webinar we will point out a possible approach on how to establish liquid biopsy in breast cancer using NGS.
Presented by:
Webinar on-demand:
Pushing the boundaries
The limit of detection in NGS liquid biopsy
July 8, 2021
NGS laboratories must comply with numerous regulations and guidelines, and strive, at the same time, to deliver the best possible analytical procedures. In this webinar our three speakers will showcase the latest advancements in NGS liquid biopsy technologies and demonstrate how these novel assays can be properly validated and tailored to the specific use case.
Webinar on-demand:
The IVDR and its impact on clinical diagnostics
How the IVDR will turn laboratory diagnostics in Europe upside down
May 6, 2021
Genetic diagnostic tests that are compliant with IVDD or IVDR are currently available only for a very small number of indications. Most of the genetic tests performed today are based on so-called Laboratory Developed Tests (LDT). The IVDR significantly increases the regulatory requirements for these LDTs and therefore has a high impact on the business and operation of diagnostic laboratories across Europe. In this webinar we will discuss what this means for your daily routine and how you need to deal with this challenge.
Webinar on-demand (German):
IVDR und genetische Diagnostik
Wie die IVDR die Labordiagnostik in Deutschland auf den Kopf stellen wird
February 24, 2021
Nur für eine geringe Zahl von Indikationen in der genetischen Diagnostik sind heute tatsächlich nach IVDD oder IVDR entwickelte CE-IVD-Tests verfügbar. Die meisten der aktuell durchgeführten genetischen Untersuchungen basieren auf sog. Laboratory Developed Tests (LDT). Die IVDR erhöht die regulatorischen Anforderungen an diese LDT erheblich und hat daher sehr konkrete Auswirkungen auf die tägliche Arbeit von Diagnostik-Labors in Deutschland. Was das für Sie bedeutet und wie Sie mit dieser Herausforderung umgehen müssen, erfahren Sie in diesem Webinar.
Webinar on-demand:
Liquid biopsy in breast cancer using NGS
September 10, 2020
NGS-based liquid biopsy assays combine an ultralow detection limit with broad genomic coverage and therefore offer a much more comprehensive testing strategy. However, the complexity of the wetlab process and the data processing have previously been challenging obstacles. In our webinar we will point out a possible approach on how to establish liquid biopsy in breast cancer using NGS.
Webinar on-demand:
One assay to rule them all
Why exome analysis is ready to replace NGS panels and conventional CNV detection
September 22, 2020
Supreme target enrichment and validated NGS analysis software enable us to perform exome sequencing as a standard first step diagnostic. In this webinar, our speakers will tell you from their own perspective why exome analysis is ready to replace targeted NGS panels and conventional CNV detection as a single assay approach in clinical routine. Exome analysis is not only efficient and adequate for clinical diagnostics, it is in fact the new standard of care.
Webinar on-demand:
The challenge of variant interpretation
Leveraging genetic and clinical evidence to improve the diagnosis of rare diseases
December 9, 2020
Due to the introduction of improved, more cost efficient target capture technologies, NGS-based applications have become the standard of care in human genetics. Large NGS assays and exome analysis generate huge amounts of data that needs to be processed and interpreted and is often underutilizes in clinical practice. The identification and interpretation of relevant genetic variants to provide accurate clinical recommendations is still considered a major challenge, as various genetics and clinical aspects need to be carefully evaluated.